2023 Pharma Choice DTC/DTP Bronze Winner AbelsonTaylor, Aimmune Therapeutics, and Seres Therapeutics

AbelsonTaylor, Aimmune Therapeutics, and Seres Therapeutics

C. diff Endless Sequels Journal Ad

Since recurrent C. diff is a dire condition that keeps patients coming back, the idea of endless horror-movie sequels is a perfect fit. Shining a light on the role of the microbiome in changing the ending of the same predictable plot, this campaign shapes how people think about C. diff.

AbelsonTaylor Team Members:

Brad Graetz, Group Creative Director
Lincoln Cairns, Associate Creative Director, Copy
Michael Gedraitis, Associate Creative Director, Art
Paula Lemperis, Copy Supervisor
Andrea Park, Art Supervisor


You May Also Like

PM360 2023 Trailblazer Awards App/Digital Solution or Suite Silver Winner GoodRx

GoodRx for Providers (GoodRx) GoodRx helps brands get to the point where Rx decisions ...

2018 Pharma Choice Philanthropic Gold Winner AbelsonTaylor and Heifer International

AbelsonTaylor Heifer International East Africa Dairy Development Project For more than 20 years, AbelsonTaylor ...

Healthcare Watch June 2023

Discoveries & Innovations: NIH Finds First Treatment for Rare Skin Disorder Disabling pansclerotic morphea ...